PhaseBio Pharmaceuticals is a biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The Company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity and ease of administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects and better patient compliance.
Market capitalization (17-Sept-2020)
Closing stock price (17-Sept-2020)
|USD||Q3, 2017||Q3, 2018||Q1, 2019||Q2, 2019||Q3, 2019||Q1, 2020||Q2, 2020|
Depreciation and Amortization
Cash From Operating Activities
PhaseBio Pharmaceuticals has 139 Twitter Followers. The number of followers has increased 0.9% month over month and increased 43.9% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was PhaseBio Pharmaceuticals founded?
PhaseBio Pharmaceuticals was founded in 2002.
Who are PhaseBio Pharmaceuticals key executives?
PhaseBio Pharmaceuticals's key executives are Jonathan Mow, Clay Thorp and Susan Arnold.
How many employees does PhaseBio Pharmaceuticals have?
PhaseBio Pharmaceuticals has 22 employees.
What is PhaseBio Pharmaceuticals revenue?
Latest PhaseBio Pharmaceuticals annual revenue is $2.4 m.
What is PhaseBio Pharmaceuticals revenue per employee?
Latest PhaseBio Pharmaceuticals revenue per employee is $107.3 k.
Who are PhaseBio Pharmaceuticals competitors?
Competitors of PhaseBio Pharmaceuticals include Cosmo Pharmaceuticals, Sangamo BioSciences and PanOptica.
Where is PhaseBio Pharmaceuticals headquarters?
PhaseBio Pharmaceuticals headquarters is located at 1 Great Valley Pkwy #30, Malvern.
Where are PhaseBio Pharmaceuticals offices?
PhaseBio Pharmaceuticals has an office in Malvern.
How many offices does PhaseBio Pharmaceuticals have?
PhaseBio Pharmaceuticals has 1 office.
Receive alerts for 300+ data fields across thousands of companies